Morphic Therapeutic stock nosedives on disappointing trial data

With two Big Pharmas abandoning partnerships and its only clinical-stage drug posting less-than-encouraging data, Waltham's Morphic Therapeutic has had a rough couple of years.

PNC’s Pittsburgh president to lead Pitt trustees as interim chair

Firm of Brazilian executive sells Surfside condo for $27M

New York restaurants aren’t all-in on the city’s outdoor dining bill

Cymbal DLT reveals 50-story next phase of Raintree project in Fort Lauderdale

Federal Realty gets green light for 260 apartments in Willow Grove

Amusement center in Queensbury near Great Escape hits market for $3.5M

Hondros acquires real estate schools in Philadelphia and Tuscon

Trader Joe’s confirms interest in Fort Point store

Morphic Therapeutic stock nosedives on disappointing trial data

Previous Judge rejects, rewrites summary for Missouri abortion initiative petition

Next Regions Bank inks first jersey sponsorship deal with Nashville Predators

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

Eastern Niagara Hospital sets closing date for Lockport facility

U.S. Bank Corporate Trust unit listed as top unsecured creditor in Bally Sports North owner’s bankruptcy

Why it’s important to choose the right bank for your business (video)

My View: New federal legislation good for local banks

Long-delayed Cambridge condo project breaks ground

Kings add Downtown Commons brunch to Farm-to-Fork events

MENU

FirstStar Group

More Stories

KC’s five strongest large banks of 2018

Previous Judge rejects, rewrites summary for Missouri abortion initiative petition

Next Regions Bank inks first jersey sponsorship deal with Nashville Predators

firststargroup

Related Posts

Suggested Posts

MENU

FirstStar Group

More Stories